Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
Trevi Therapeutics Inc (NASDAQ: TRVI) closed the day trading at $7.45 down -0.93% from the previous closing price of $7.52. In other words, the price has decreased by -$0.93 from its previous closing price. On the day, 1.12 million shares were traded. TRVI stock price reached its highest trading level at $7.6 during the session, while it also had its lowest trading level at $7.3615.
Ratios:
For a better understanding of TRVI, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 22.42 and its Current Ratio is at 22.42. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on July 01, 2025, initiated with a Overweight rating and assigned the stock a target price of $25.
On May 28, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $21.
Raymond James Upgraded its Outperform to Strong Buy on March 10, 2025, whereas the target price for the stock was revised from $9 to $29.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 25 ’25 when SCIASCIA THOMAS sold 2,631 shares for $6.60 per share. The transaction valued at 17,365 led to the insider holds 221,373 shares of the business.
GOOD JENNIFER L sold 5,263 shares of TRVI for $34,625 on Mar 21 ’25. The President & CEO now owns 213,313 shares after completing the transaction at $6.58 per share. On Mar 21 ’25, another insider, GOOD JENNIFER L, who serves as the Officer of the company, bought 5,263 shares for $6.58 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRVI now has a Market Capitalization of 907238656 and an Enterprise Value of 704243584.
Stock Price History:
The Beta on a monthly basis for TRVI is 0.72, which has changed by 1.6140351 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, TRVI has reached a high of $8.11, while it has fallen to a 52-week low of $2.36. The 50-Day Moving Average of the stock is 10.82%, while the 200-Day Moving Average is calculated to be 41.43%.
Shares Statistics:
Over the past 3-months, TRVI traded about 1.90M shares per day on average, while over the past 10 days, TRVI traded about 1338080 shares per day. A total of 121.78M shares are outstanding, with a floating share count of 80.73M. Insiders hold about 33.70% of the company’s shares, while institutions hold 60.17% stake in the company. Shares short for TRVI as of 1753920000 were 10160448 with a Short Ratio of 5.34, compared to 1751241600 on 9184965. Therefore, it implies a Short% of Shares Outstanding of 10160448 and a Short% of Float of 9.67.
Earnings Estimates
The current rating of Trevi Therapeutics Inc (TRVI) is the result of assessments by 8.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.1 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.38 and -$0.44 for the fiscal current year, implying an average EPS of -$0.4. EPS for the following year is -$0.49, with 8.0 analysts recommending between -$0.24 and -$0.65.
